Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience | Zendy

Zehra Yaşar | Zendy; Ufuk Yılmaz | Zendy; Ulku Yılmaz | Zendy; EsraKorkmaz Kıraklı | Zendy; Şükran Ülger | Zendy; Yasemin Özdoğan | Zendy; NilgünYılmaz Demirci | Zendy; Serhat Erol | Zendy; Ilker Ozdogan | Zendy; Burcu Şahin | Zendy; Deniz Köksal | Zendy; Cimen Akcay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience

Author(s) -

Zehra Yaşar,

Ufuk Yılmaz,

Ulku Yılmaz,

EsraKorkmaz Kıraklı,

Şükran Ülger,

Yasemin Özdoğan,

NilgünYılmaz Demirci,

Serhat Erol,

Ilker Ozdogan,

Burcu Şahin,

Deniz Köksal,

Cimen Akcay

Publication year - 2016

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.163682

Subject(s) - medicine , chemoradiotherapy , stage (stratigraphy) , radiation therapy , lung cancer , etoposide , cisplatin , confidence interval , gastroenterology , surgery , chemotherapy , oncology , paleontology , biology

Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research